問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Radiation Therapy

Division of Urology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

An Nan Hospital-China Medical Univeristy (在職)

更新時間：2023-09-19

林精湛Lin, Ching-Chan
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • linchin13256@yahoo.com.tw

Recruiting Trial

132Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林精湛

List

229Cases

2021-04-01 - 2029-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2020-07-31 - 2021-12-07

Phase II

Randomized, double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of RV521 in the treatment of adult subjects who have undergone hematopoietic cell transplantation (HCT) with a documented upper respiratory tract infection (URTI) with respiratory syncytial virus (RSV).

  • Condition/Disease

    respiratory syncytial virus

  • Test Drug

    RV521

Participate Sites
5Sites

Recruiting5Sites

2019-09-01 - 2022-12-31

Phase II

A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)

  • Condition/Disease

    Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies

  • Test Drug

    ME-401

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2017-01-01 - 2021-11-17

Phase III

A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation

  • Condition/Disease

    Corticosteroid Refractory Acute Graft vs Host Disease

  • Test Drug

    INC424

Participate Sites
3Sites

Terminated2Sites

2019-12-01 - 2025-12-31

Phase II

A Phase II Open-label, Single-arm, Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

  • Condition/Disease

    Graft vs Host Disease

  • Test Drug

    INC424

Participate Sites
2Sites

Recruiting2Sites

2021-12-01 - 2029-05-10

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2015-04-01 - 2022-04-22

Phase III

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma (MM)

  • Test Drug

    Pomalidomide

Participate Sites
8Sites

Terminated7Sites

2017-02-10 - 2020-01-30

Phase III

A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)

  • Condition/Disease

    Chronic Graft Versus Host Disease (cGVHD)

  • Test Drug

    Imbruvica®

Participate Sites
3Sites

Terminated2Sites

2020-09-20 - 2024-02-22

Phase I

A Phase I, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of OBI-866/OBI-821, a Novel Anti-Stage-Specific Embryonic Antigen-4 (SSEA-4) Active Immunotherapy, in Patients with Advanced/Metastatic Cancers of the Ovary, Kidney, Brain, Pancreas, Breast or Lung

  • Condition/Disease

    Cancers of the Ovary, Kidney, Brain, Pancreas, Breast or Lung

  • Test Drug

    OBI-866 (SSEA-4) / OBI-821 (adjuvant)

Participate Sites
2Sites

Recruiting2Sites

白禮源
China Medical University Hospital

Division of Hematology & Oncology

2020-08-01 - 2022-08-31

Phase I/II

A Phase I/II, Open Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI 888 in Patients with Locally Advanced or Metastatic Solid Tumors.

  • Condition/Disease

    Metastatic Solid Tumors / Locally Advanced Solid Tumors

  • Test Drug

    OBI 888

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

1 19 20 21 22 23
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB